Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics receives FDA minutes on reproxalap NDA resubmission path

Neutral Impact 3 of 5 legal/regulatory Written later

Aldeyra received minutes from a June 10, 2026 Type A meeting with the FDA about potential resubmission of the New Drug Application for reproxalap, a treatment for dry eye disease. The company has asked the FDA for a clarification of the minutes and plans to request a Type D meeting to discuss resubmission, which is expected by the end of the third quarter of 2026.

Key points

  • Type A meeting with the FDA held June 10, 2026; minutes received July 14, 2026
  • Clarification of the minutes requested from the FDA on July 15, 2026
  • Type D meeting on NDA resubmission expected by end of third quarter 2026

The filing

CompanyAldeyra Therapeutics, Inc. (ALDX)
Form8-K, current report
Filed with the SECJul 15, 2026, 4:46 PM ET
Accession number0001193125-26-304880

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.